Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 8/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
| ▸ | AADAC | P22760 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8902955 | 0.90 | AR (0.47) | ARCYP3A4PGRALDH1A1HTT | |
| SCHEMBL31601892 | 0.90 | AR (0.47) | ARCYP3A4PGRALDH1A1HTT | |
| SCHEMBL462770 | 0.86 | NPSR1 (0.48) | ARCYP3A4PGRALDH1A1HTT | |
| SCHEMBL31495022 | 0.84 | AR (0.43) | ARCYP3A4PGRALDH1A1HTT | |
| SCHEMBL1797636 | 0.84 | AR (0.43) | ARCYP3A4PGRALDH1A1HTT | |
| SCHEMBL7746027 | 0.82 | AR (0.41) | ARCYP3A4PGRALDH1A1HTT | |
| SCHEMBL6266898 | 0.81 | AR (0.43) | ARCYP3A4PGRALDH1A1HTT | |
| SCHEMBL22636966 | 0.81 | AR (0.42) | ARCYP3A4PGRALDH1A1HTT | |
| SCHEMBL239425 | 0.80 | PDK1 (0.40) | ARCYP3A4PGRALDH1A1HTT | |
| SCHEMBL1192664 | 0.80 | NPSR1 (0.48) | ARCYP3A4PGRALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7214691-B2 | 2-substituted benzimidazole derivatives as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders | SCHERING CORPORATION (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214691-B2 | 2-substituted benzimidazole derivatives as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders | SCHERING CORPORATION (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214691-B2 | 2-substituted benzimidazole derivatives as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders | SCHERING CORPORATION (US) | 2007-05-08 | — | — | US | disclosed |
| EP-1660478-A1 | 2-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS SELECTIVE MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY AND RELATED DISORDERS | SCHERING CORPORATION (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005021528-A1 | 2-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS SELECTIVE MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY AND RELATED DISORDERS | SCHERING CORPORATION (US) | 2005-03-10 | — | — | WO | disclosed |
| US-20050049269-A1 | 2-Substituted benzimidazole derivatives as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders | SCHERING CORPORATION | 2005-03-03 | — | — | US | disclosed |
| EP-0596358-B1 | 0-Phenylenediamines containing fluoroakyl(ene) groups and their use as intermediates in the preparation of benzimidazoles | BAYER AG (DE) | 1998-10-28 | — | — | EP | disclosed |
| US-5484953-A | CHEMICAL INTERMEDIATES FOR BENZIMIDAZOLES FOR INSECTICIDES OR NEMATOCIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1996-01-16 | — | — | US | disclosed |
| EP-0596358-A1 | 0-Phenylenediamines containing fluoroakyl(ene) groups and their use as intermediates in the preparation of benzimidazoles | BAYER AG (DE) | 1994-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049269-A1 | 2-Substituted benzimidazole derivatives as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders | MCHR1, NPY1R, MCHR2 | AR 72/4885CYP3A4 787/4885PGR 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.